Medetomidine: New hidden danger in opioid withdrawal for inmates
The challenges faced by individuals in rural Pennsylvania jails dealing with opioid withdrawal have been exacerbated by the emergence of medetomidine as an adulterant in the illicit drug supply. This powerful tranquilizer has led to severe withdrawal symptoms that are often difficult to manage, especially in correctional settings where resources and protocols may be lacking.
Lillian, a pseudonym used to protect her identity, shared her harrowing experience of withdrawing from fentanyl laced with medetomidine while in jail. She described experiencing debilitating symptoms, including “brain zaps” and the need for constant support from corrections officers to prevent falls. Despite the severity of her withdrawal, Lillian only received ibuprofen and Pepto-Bismol, which she described as inadequate for the excruciating symptoms she was experiencing.
The issue of medetomidine withdrawal is becoming more prevalent across the country, with the Centers for Disease Control and Prevention reporting its presence in drug samples from various sentinel sites. Jails, in particular, are struggling to effectively treat individuals going through medetomidine withdrawal due to the complexity of the symptoms and the lack of appropriate medications and protocols.
In Pittsburgh, where medetomidine has had a significant impact, efforts are being made to improve the treatment of individuals experiencing withdrawal. The Allegheny County Jail has worked with experts in addiction medicine to develop protocols for managing medetomidine withdrawal, resulting in better outcomes for patients like Chris, who received prompt and appropriate treatment upon arrival at the jail. However, even with these interventions, some individuals may still face life-threatening complications, as seen in Chris’s case, where he suffered a heart attack due to medetomidine withdrawal.
The availability of medications for opioid use disorder and withdrawal in jails is crucial for addressing the growing problem of medetomidine withdrawal. Advocates like Bethany Hallam and Stuart Fisk have been instrumental in expanding access to medication-assisted treatment in Allegheny County Jail, demonstrating the positive impact of offering a range of FDA-approved medications to individuals with opioid use disorder.
Despite the progress made in some jails, many facilities still lack the resources and protocols to effectively manage medetomidine withdrawal. Rapid and accurate detection of medetomidine is essential for providing appropriate treatment, but current testing methods are not designed to identify this specific substance. Jails must become more proactive in identifying and treating medetomidine withdrawal, potentially by offering medications like buprenorphine to quickly clarify the situation and provide relief to affected individuals.
The issue of medication access in jails is further complicated by legal restrictions and funding challenges. While guidelines exist that recommend offering medications for opioid use disorder, many jails still do not provide these treatments. The National Sheriffs’ Association has raised concerns about the Federal Medicaid Inmate Exclusion Policy, highlighting the need to address the constitutional rights of individuals in custody.
In conclusion, the emergence of medetomidine in the illicit drug supply has created new challenges for jails in managing opioid withdrawal. By implementing evidence-based protocols, expanding access to medications, and increasing awareness of medetomidine withdrawal, jails can better support individuals going through this complex and potentially life-threatening process.
